OraSure's Intercept Oral Fluid Drug Test Results Comparable to Urine Drug Screening According to Landmark Five-Year Analysis
05 November 2008 - 5:35AM
Business Wire
OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that
findings from a recent large-scale study of laboratory-based oral
fluid drug testing results are comparable to urine drug testing
positive rates for the same classes of drugs. The 650,000 oral
fluid laboratory test results analyzed, of which 98% were conducted
with the Intercept� oral fluid drug testing system, were collected
over a five-year period of time in the non-federally regulated
workplace market. The results of this expansive study, which was
sponsored by the U.S. Department of Health and Human Services
Substance Abuse and Mental Health Services Administration (SAMHSA),
were presented by Dr. J. Michael Walsh on October 29, 2008 at the
annual meeting of the Society of Forensic Toxicologists (SOFT). A
copy of the abstract can be found later this week at the SOFT web
site at www.soft-tox.org. �The results of this analysis clearly
indicate that oral fluid laboratory drug testing and in particular
our Intercept� drug test are producing comparable outcomes to
urine-based testing,� said Dr. Stephen Lee, OraSure�s Chief Science
Officer. Developed and manufactured by OraSure Technologies, the
Intercept� Drug Test is the only FDA-cleared in vitro diagnostic
laboratory-based oral fluid testing system used for detecting
commonly abused drugs such as marijuana, cocaine, opiates, PCP and
amphetamines (including methamphetamine and ecstasy) and for
detecting barbiturates, methadone and benzodiazepines. Intercept�
testing is currently being used in workplace, drug treatment and
criminal justice testing markets, as well as in public school
systems. About OraSure Technologies OraSure Technologies develops,
manufactures and markets oral fluid specimen collection devices
using proprietary oral fluid technologies, diagnostic products
including immunoassays and other in vitro diagnostic tests, and
other medical devices. These products are sold in the United States
as well as internationally to various clinical laboratories,
hospitals, clinics, community-based organizations and other public
health organizations, distributors, government agencies,
physicians� offices, and commercial and industrial entities.
OraSure Technologies is the leading supplier of oral-fluid testing
solutions for drugs of abuse and for the detection of antibodies to
HIV. For more information on the Company, please go to
www.orasure.com.
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jul 2023 to Jul 2024